ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

F182112

Its studies are mostly in Lupus Erythematosus, Systemic · Multiple Myeloma, led by Lunan Pharmaceutical Group.

Furthest: phase 1, since Jul 21, 20212 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lunan Pharmaceutical Group21 open or runningphase 1since Jul 21, 2021Jul 21, 2021Dec 31, 2027phase 1 · NCT07829614

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2021First study: phase 1 study in RecurrenceFirst studyNCT04984434 · 68 enrolled · China
  2. Sep 2, 2026Phase 1 study in Lupus Erythematosus, SystemicNCT07829614 · 64 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07829614

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07829614Lupus Erythematosus, Systemic · China1RecruitingDec 31, 202764
NCT04984434Recurrence · China1UNKNOWNJul 30, 202368

How it is read

Names in the registry

  • “F182112”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
F182112 (Lunan Pharmaceutical Group): development program | ClinicalTrials.gg